AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
AIM ImmunoTech (NYSE American: AIM) has scheduled a conference call and webcast for November 15, 2024, at 8:30 AM ET to discuss their third quarter 2024 operational and financial results. The event will be led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Investors can join by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international). The webcast will be available on the company's website and archived for 90 days.
AIM ImmunoTech (NYSE American: AIM) ha programmato una chiamata in conferenza e un webcast per 15 Novembre 2024, alle 8:30 AM ET per discutere i risultati operativi e finanziari del terzo trimestre 2024. L'evento sarà guidato dal CEO Thomas K. Equels e dal Direttore Scientifico Christopher McAleer, PhD. Gli investitori possono partecipare componendo il numero (877) 407-9219 (nazionale) o (201) 689-8852 (internazionale). Il webcast sarà disponibile sul sito web dell'azienda e archiviato per 90 giorni.
AIM ImmunoTech (NYSE American: AIM) ha programado una llamada de conferencia y un webcast para el 15 de noviembre de 2024, a las 8:30 AM ET para discutir los resultados operativos y financieros del tercer trimestre de 2024. El evento será liderado por el CEO Thomas K. Equels y el Oficial Científico Christopher McAleer, PhD. Los inversores pueden unirse marcando el (877) 407-9219 (nacional) o (201) 689-8852 (internacional). El webcast estará disponible en el sitio web de la empresa y se archivará durante 90 días.
AIM ImmunoTech (NYSE American: AIM)는 2024년 11월 15일 오전 8시 30분 ET에 2024년 3분기 운영 및 재무 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 이 행사는 CEO Thomas K. Equels와 과학 책임자 Christopher McAleer 박사가 진행할 것입니다. 투자자들은 (877) 407-9219 (국내) 또는 (201) 689-8852 (국제)로 전화하여 참여할 수 있습니다. 웹캐스트는 회사 웹사이트에서 제공되며 90일 동안 보관됩니다.
AIM ImmunoTech (NYSE American: AIM) a programmé une conférence téléphonique et un webinaire pour le 15 novembre 2024 à 8h30 ET afin de discuter des résultats opérationnels et financiers du troisième trimestre de 2024. L'événement sera dirigé par le PDG Thomas K. Equels et le responsable scientifique Christopher McAleer, PhD. Les investisseurs peuvent participer en composant le (877) 407-9219 (national) ou le (201) 689-8852 (international). Le webinaire sera disponible sur le site web de l'entreprise et sera archivé pendant 90 jours.
AIM ImmunoTech (NYSE American: AIM) hat eine Telefonkonferenz und ein Webcast für den 15. November 2024, um 8:30 Uhr ET angesetzt, um die operativen und finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen. Die Veranstaltung wird von CEO Thomas K. Equels und dem Wissenschaftlichen Leiter Christopher McAleer, PhD, geleitet. Investoren können teilnehmen, indem sie (877) 407-9219 (national) oder (201) 689-8852 (international) anrufen. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und 90 Tage lang archiviert.
- None.
- None.
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET.
The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com, and will be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
When is AIM ImmunoTech (AIM) releasing Q3 2024 earnings?
How can investors join AIM ImmunoTech's Q3 2024 earnings call?
Who will host AIM ImmunoTech's Q3 2024 earnings call?
